Published in J Exp Med on January 15, 2001
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med (2002) 2.89
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol (2006) 2.81
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Limited durability of viral control following treated acute HIV infection. PLoS Med (2004) 2.16
CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest (2001) 2.15
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol (2002) 2.14
Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol (2004) 2.07
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Portable flanking sequences modulate CTL epitope processing. J Clin Invest (2007) 1.72
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol (2001) 1.65
Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61
Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest (2006) 1.59
Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol (2001) 1.57
Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol (2008) 1.54
Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol (2005) 1.52
Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One (2010) 1.50
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest (2002) 1.50
Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol (2003) 1.49
Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol (2014) 1.44
Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol (2001) 1.42
Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol (2005) 1.41
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol (2003) 1.40
Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol (2010) 1.39
Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol (2003) 1.38
Timely triggering of homeostatic mechanisms involved in the regulation of T-cell levels in SIVsm-infected sooty mangabeys. Blood (2005) 1.29
Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire. Blood (2005) 1.28
CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med (2010) 1.27
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol (2002) 1.24
Loss of T cell responses following long-term cryopreservation. J Immunol Methods (2007) 1.23
Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J Virol (2001) 1.23
Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology (2009) 1.21
Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol (2005) 1.21
The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20
HIV-1 envelope subregion length variation during disease progression. PLoS Pathog (2010) 1.20
Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology (2007) 1.19
Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol (2009) 1.19
Persistence of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression. J Virol (2001) 1.18
Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One (2009) 1.11
The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol (2011) 1.06
Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment. J Immunol (2008) 1.05
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis (2009) 1.05
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS (2008) 1.05
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med (2015) 1.04
Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc Natl Acad Sci U S A (2003) 1.04
Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol (2008) 1.03
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One (2013) 1.02
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses (2010) 1.02
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis (2010) 1.02
Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol (2010) 1.00
Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol (2011) 0.98
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol (2002) 0.97
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
CD8 T cell persistence in treated HIV infection. Curr Opin HIV AIDS (2014) 0.97
Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol (2008) 0.96
Standardized Serum-Free Cryomedia Maintain Peripheral Blood Mononuclear Cell Viability, Recovery, and Antigen-Specific T-Cell Response Compared to Fetal Calf Serum-Based Medium. Biopreserv Biobank (2011) 0.95
Immunophenotypic alterations in acute and early HIV infection. Clin Immunol (2007) 0.94
HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol (2006) 0.92
Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. Clin Exp Immunol (2007) 0.92
Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection. J Infect Dis (2011) 0.92
CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects. J Transl Med (2004) 0.92
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90
Lack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals. J Infect Dis (2010) 0.90
Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol (2002) 0.89
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy. J Virol (2010) 0.88
Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLoS Pathog (2013) 0.87
Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clin Exp Immunol (2008) 0.87
The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection. Curr Infect Dis Rep (2002) 0.87
Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol (2004) 0.86
Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection. J Virol (2006) 0.86
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 7.68
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998) 4.80
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
HIV quasispecies and resampling. Science (1996) 3.98
Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol (1997) 3.93
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 3.22
Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses (1997) 2.91
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 2.54
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.15
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest (1999) 2.00
Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. J Virol (2000) 1.84
Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol (2000) 1.79
T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr Opin Immunol (1999) 1.68
The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol (2000) 1.63
Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 1.59
Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis (1999) 1.47
Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS (1999) 1.31
HIV-1 evolution and disease progression. Science (1996) 1.20
Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses (1997) 1.15
Persistent infection of baboons and rhesus monkeys with different strains of HIV-2. Virology (1991) 1.14
The great escape - AIDS viruses and immune control. Nat Med (1999) 1.07
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 7.68
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA (1987) 7.24
Community-based approaches to HIV treatment in resource-poor settings. Lancet (2001) 7.13
Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains. Science (1973) 7.12
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health (1987) 5.78
Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc Natl Acad Sci U S A (1987) 5.65
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
Photonic detection of bacterial pathogens in living hosts. Mol Microbiol (1995) 5.24
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998) 4.80
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 4.51
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Human immunodeficiency viruses. Science (1986) 4.34
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
HIV quasispecies and resampling. Science (1996) 3.98
Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol (1997) 3.93
Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet (1997) 3.93
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med (1998) 3.81
Condoms prevent transmission of AIDS-associated retrovirus. JAMA (1986) 3.78
From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis (2004) 3.76
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell (1987) 3.65
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet (1996) 3.54
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
Viral transduction of c-myc gene in naturally occurring feline leukaemias. Nature (1984) 3.39
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis (1985) 3.31
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 3.22
Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet (1988) 3.21
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Molecular cloning of AIDS-associated retrovirus. Nature (1985) 3.16
Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A (1987) 3.14
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Molecular epidemiology of HIV transmission in a dental practice. Science (1992) 3.10
SIV adaptation to human cells. Nature (1989) 3.09
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 3.00
Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther (2001) 2.95